EP1601357A4 - HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS - Google Patents

HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS

Info

Publication number
EP1601357A4
EP1601357A4 EP04719237A EP04719237A EP1601357A4 EP 1601357 A4 EP1601357 A4 EP 1601357A4 EP 04719237 A EP04719237 A EP 04719237A EP 04719237 A EP04719237 A EP 04719237A EP 1601357 A4 EP1601357 A4 EP 1601357A4
Authority
EP
European Patent Office
Prior art keywords
synthesis
methods
kinase inhibitors
heterocyclic kinase
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04719237A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1601357A1 (en
Inventor
M Arshad Siddiqui
David Belanger
Chaoyang Dai
Lianyun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1601357A1 publication Critical patent/EP1601357A1/en
Publication of EP1601357A4 publication Critical patent/EP1601357A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04719237A 2003-03-10 2004-03-10 HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS Withdrawn EP1601357A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US453457P 2003-03-10
US46091003P 2003-04-07 2003-04-07
US460910P 2003-04-07
US46302503P 2003-04-15 2003-04-15
US463025P 2003-04-15
US50271003P 2003-09-12 2003-09-12
US502710P 2003-09-12
PCT/US2004/007286 WO2004080463A1 (en) 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis

Publications (2)

Publication Number Publication Date
EP1601357A1 EP1601357A1 (en) 2005-12-07
EP1601357A4 true EP1601357A4 (en) 2007-10-03

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04719237A Withdrawn EP1601357A4 (en) 2003-03-10 2004-03-10 HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS

Country Status (5)

Country Link
EP (1) EP1601357A4 (enExample)
JP (1) JP2006519846A (enExample)
CA (1) CA2518398A1 (enExample)
MX (1) MXPA05009722A (enExample)
WO (1) WO2004080463A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
JP4976394B2 (ja) * 2005-08-17 2012-07-18 シェーリング コーポレイション 新規な高親和性のキノリンベースのキナーゼリガンド
EP3719018B1 (en) 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
WO2008059370A2 (en) 2006-11-17 2008-05-22 Pfizer Japan Inc. Substituted bicyclocarboxyamide compounds
DE602007008469D1 (de) 2006-12-07 2010-09-23 Hoffmann La Roche 2-aminochinoline als 5-ht(5a)-rezeptorantagonisten
JP5671236B2 (ja) 2007-03-14 2015-02-18 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼ阻害剤としてのピラゾロ（３，４−ｂ）ピリジン誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008150364A1 (en) * 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
US8614326B2 (en) * 2007-08-22 2013-12-24 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
AU2008303602A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5HT5A receptor antagonists
NZ585261A (en) 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
EP2215089B1 (en) 2007-11-02 2012-06-27 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
CN101959876A (zh) * 2008-03-05 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉类化合物
BRPI0909824A2 (pt) * 2008-03-07 2019-03-06 F. Hoffmann-La Roche Ag 2-aminoquinolinas
AU2009221389A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinoline derivatives
WO2009112395A1 (en) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht5a receptor antagonists
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
PL2401267T3 (pl) 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
WO2010101949A1 (en) * 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
HRP20230248T1 (hr) * 2009-06-12 2023-04-14 Abivax Spojevi korisni za liječenje preranog starenja, te naročito progerije
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
SG181719A1 (en) 2009-12-17 2012-07-30 Schering Corp Quinoline amide m1 receptor positive allosteric modulators
BR112012018865A2 (pt) 2010-01-29 2016-04-12 Boehringer Ingelheim Int naftiridinas substituídas e seu uso como inibidores de quinase syk
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
CA2805932A1 (en) * 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
CN103298805A (zh) 2010-09-01 2013-09-11 埃姆比特生物科学公司 喹唑啉化合物及其使用方法
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2922544B1 (en) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
PT3212629T (pt) * 2014-10-31 2019-02-04 Genoscience Pharma Sas Substituído 2,4 diamino-quinoline como novos agentes anti cancro
ES2849560T3 (es) * 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
AU2018286247B2 (en) * 2017-06-14 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
WO2019023278A1 (en) * 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
ES2971892T3 (es) * 2018-12-14 2024-06-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd Formas cristalinas del inhibidor de Syk sal hidrocloruro de 5-fluoro-1-metil-3-[[5-[4-(3-oxetanil)-1-piperazinil]-2-piridinil]amino]-6-(1H-pirazol-3-il)-2(1H)-quinolinona (1:1)
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SI4175719T1 (sl) 2020-07-02 2025-07-31 Incyte Corporation Triciklične sečninske spojine kot zaviralci jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
JP2024543981A (ja) * 2021-12-01 2024-11-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症性疾患の処置に使用するためのｉｒａｐアミノペプチダーゼ阻害剤の使用
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (en) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2003078404A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Pyrimidine derivatives
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004081531A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Ligand analysis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
FR6103M (enExample) * 1967-02-22 1968-06-10
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPH05310702A (ja) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd 抗炎症剤、免疫調整剤およびキノリン−２，４−ジカルボン酸ジアミド誘導体
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
AU3386700A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
CN100376557C (zh) * 2001-05-21 2008-03-26 霍夫曼-拉罗奇有限公司 作为神经肽y受体的配体的喹啉衍生物
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0102858D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (en) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2003078404A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Pyrimidine derivatives
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004081531A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Ligand analysis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASEBE, M.; ET AL., TETRAHEDRON LETTERS, vol. 29, no. 48, 1988, pages 6287 - 6290, XP002445489 *
ILLUMINATI, G.; GILMAN, H., J. AM. CHEM. SOC., vol. 71, 1949, pages 3349 - 3351, XP002445491 *
SARGENT, H., J. AM. CHEM. SOC., vol. 68, 1964, pages 2688 - 2692, XP002445490 *
See also references of WO2004080463A1 *
WEISS, M.J.; HAUSER, C.R., J. AM. CHEM. SOC., vol. 71, 1949, pages 2026 - 2027, XP002445492 *

Also Published As

Publication number Publication date
JP2006519846A (ja) 2006-08-31
WO2004080463A1 (en) 2004-09-23
CA2518398A1 (en) 2004-09-23
MXPA05009722A (es) 2006-03-09
EP1601357A1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
EP1507541A4 (en) HEMMER AND APPLICATION METHOD THEREFOR
EP1606285A4 (en) NEW IDO HEMMER AND APPLICATION PROCEDURES
EP1691812A4 (en) GTPASE INHIBITORS AND METHOD OF USE
EP1603567A4 (en) TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
EP1723227A4 (en) NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
EP1831207A4 (en) AMINO-PRIMIDINE COMPOUNDS AND METHOD OF USE
EP1644323A4 (en) HISTONDEACETYLASEINHIBITORS AND METHODS FOR THEIR APPLICATION
EP1181293A4 (en) CUCURBITURILE AND METHOD FOR THEIR PRODUCTION
IS7599A (is) Heterósýklískir kínasatálmar
EP1583950A4 (en) TEST CASSETTES AND METHOD OF USE THEREOF
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHOD OF USE
EP1603568A4 (en) ISOCHINOLINE DERIVATIVES AND METHOD OF USE THEREOF
MA29029B1 (fr) Composes de thiadiazole et leurs procedes d'utilisation
DE60313289D1 (de) Kontrollierte synthese von ziprasidon
EP1855833A4 (en) PLASMATA AND METHOD OF USE THEREOF
PL376789A1 (pl) Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
EP1706791A4 (en) PHOTORESISTIC COMPOSITIONS AND USE PROCESSES
EP1722797A4 (en) ISOCHINOLINE DERIVATIVES AND METHOD FOR THE APPLICATION THEREOF
EP1476150A4 (en) CARBOXY FULLERES AND USE METHOD THEREFOR
EP1638513A4 (en) HIGHLY UNAVAILABLE CONNECTIONS AND METHOD OF USE THEREFOR
EP1735456A4 (en) POLYMERIC COMPOSITION AND ASSOCIATED METHOD OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077021

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070830

17Q First examination report despatched

Effective date: 20080603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100529

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077021

Country of ref document: HK